Comparison of safety outcomes of CIBMTR with those of ELIANA and JULIET trials
| . | ALL . | NHL . | ||
|---|---|---|---|---|
| End point . | CIBMTR (n = 255) . | ELIANA (n = 79) . | CIBMTR (n = 155) . | JULIET (n = 115) . |
| CRS | ||||
| Any, n (%) | 140 (54.9) | 61 (77.2) | 70 (45.2) | 66 (57.4) |
| Grade ≥3, n (%) | 41 (16.1) | 38 (48.1) | 7 (4.5) | 26 (22.6) |
| Time to onset, d | ||||
| Median | 6 | 3 | 4 | 3 |
| Range | 1-27 | 1-22 | 1-14 | 1-51 |
| Duration, d | ||||
| Median | 7 | 8 | 5 | 7 |
| Range | 1-76 | 1-36 | 1-33 | 2-30 |
| Neurotoxicity | ||||
| Any, n (%) | 69 (27.1) | 31 (39.2) | 28 (18.1) | 23 (20.0) |
| Grade ≥3, n (%) | 23 (9.0) | 10 (12.7) | 8 (5.1) | 13 (11.3) |
| Time to onset, d | ||||
| Median | 7 | 8 | 8 | 6 |
| Range | 1-80 | 2-489 | 2-33 | 1-323 |
| Duration, d | ||||
| Median | 7 | 7 | 6.5 | 13 |
| Range | 1-94 | 1-50 | ||
| . | ALL . | NHL . | ||
|---|---|---|---|---|
| End point . | CIBMTR (n = 255) . | ELIANA (n = 79) . | CIBMTR (n = 155) . | JULIET (n = 115) . |
| CRS | ||||
| Any, n (%) | 140 (54.9) | 61 (77.2) | 70 (45.2) | 66 (57.4) |
| Grade ≥3, n (%) | 41 (16.1) | 38 (48.1) | 7 (4.5) | 26 (22.6) |
| Time to onset, d | ||||
| Median | 6 | 3 | 4 | 3 |
| Range | 1-27 | 1-22 | 1-14 | 1-51 |
| Duration, d | ||||
| Median | 7 | 8 | 5 | 7 |
| Range | 1-76 | 1-36 | 1-33 | 2-30 |
| Neurotoxicity | ||||
| Any, n (%) | 69 (27.1) | 31 (39.2) | 28 (18.1) | 23 (20.0) |
| Grade ≥3, n (%) | 23 (9.0) | 10 (12.7) | 8 (5.1) | 13 (11.3) |
| Time to onset, d | ||||
| Median | 7 | 8 | 8 | 6 |
| Range | 1-80 | 2-489 | 2-33 | 1-323 |
| Duration, d | ||||
| Median | 7 | 7 | 6.5 | 13 |
| Range | 1-94 | 1-50 | ||